---
layout: default
title: Pitolisant
description: "Pitolisant çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 129
evidence_level: L3
indication_count: 3
---

# Pitolisant

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pitolisant è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Pitolisant å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Pitolisant ç‚ºé¸æ“‡æ€§çµ„ç¹”èƒº H3 å—é«”åå‘æ¿€å‹•åŠ‘ï¼ŒTxGNN é æ¸¬å°å¤±çœ åŠ ADHD æœ‰æ½›åœ¨ç™‚æ•ˆï¼Œå·²æœ‰æ–‡ç»æ”¯æŒå…¶ä¿ƒé†’åŠèªçŸ¥å¢å¼·ä½œç”¨ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“å­¸å | Pitolisant (å”¯é†’) |
| DrugBank ID | DB11642 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | çŒç¡ç—‡ï¼ˆä¼´éš¨æˆ–æœªä¼´éš¨çŒå€’ï¼‰ã€é˜»å¡æ€§ç¡çœ å‘¼å¸ä¸­æ­¢å¼•èµ·çš„æ—¥é–“éåº¦å—œç¡ |
| TxGNN é æ¸¬æ–°é©æ‡‰ç—‡ | insomnia (disease)ã€attention deficit-hyperactivity disorderã€faciodigitogenital syndrome |
| å°ç£è¨±å¯è­‰æ•¸ | 4 å¼µ |
| æœ€é«˜è­‰æ“šç­‰ç´š | L3 (è§€å¯Ÿæ€§ç ”ç©¶/æ–‡ç»å›é¡§) |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. insomnia (disease)</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.71%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Pitolisant ä½œç‚º H3 å—é«”åå‘æ¿€å‹•åŠ‘ï¼Œå…¶é æ¸¬çš„æ–°é©æ‡‰ç—‡åœ¨æ©Ÿè½‰ä¸Šå…·æœ‰åˆç†æ€§ï¼š</p>

<ol>
<li><strong>å¤±çœ  (Insomnia)</strong>ï¼šH3 å—é«”é˜»æ–·å¯å¢åŠ è…¦å…§çµ„ç¹”èƒºé‡‹æ”¾ï¼Œä¿ƒé€²è¦ºé†’ã€‚é›–çœ‹ä¼¼çŸ›ç›¾ï¼Œä½†æ”¹å–„ç¡çœ -è¦ºé†’é€±æœŸèª¿æ§å¯èƒ½å°æŸäº›å¤±çœ é¡å‹æœ‰ç›Š</li>
<li><strong>æ³¨æ„åŠ›ä¸è¶³éå‹•ç—‡ (ADHD)</strong>ï¼šçµ„ç¹”èƒºç³»çµ±åƒèˆ‡æ³¨æ„åŠ›åŠèªçŸ¥åŠŸèƒ½èª¿æ§ï¼ŒH3 å—é«”æ‹®æŠ—åŠ‘å¯å¢å¼·è¦ºé†’åŠæ³¨æ„åŠ›</li>
<li><strong>Aarskog ç—‡å€™ç¾¤</strong>ï¼šé æ¸¬æ©Ÿè½‰ä¸æ˜ç¢ºï¼Œå¯èƒ½ç‚ºæ¨¡å‹å‡é™½æ€§</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>é æ¸¬é©æ‡‰ç—‡</th>
<th>è‡¨åºŠè©¦é©—æ•¸</th>
<th>ä»£è¡¨æ€§è©¦é©—</th>
</tr>
</thead>
<tbody>
<tr>
<td>å¤±çœ </td>
<td>1 (é–“æ¥)</td>
<td>NCT02800083: Pitolisant æ²»ç™‚é…’ç²¾ä½¿ç”¨éšœç¤™ï¼ˆè©•ä¼°ç¡çœ ä½œç‚ºæ¬¡è¦æŒ‡æ¨™ï¼‰</td>
</tr>
<tr>
<td>ADHD</td>
<td>0</td>
<td>ç›´æ¥è©¦é©—ç„¡ï¼Œä½†æœ‰ç›¸é—œæ–‡ç»è¨è«–</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>### å¤±çœ  (Insomnia)</p>
<p><strong>è­‰æ“šç­‰ç´šï¼šL3 (è§€å¯Ÿæ€§ç ”ç©¶/å›é¡§æ€§æ–‡ç»)</strong></p>

<table>
<thead>
<tr>
<th>PMID</th>
<th>æ¨™é¡Œ</th>
<th>å¹´ä»½</th>
<th>é‡é»ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td>34225942</td>
<td>Histamine receptors in health and disease</td>
<td>2021</td>
<td>ç¶œè¿° H3 å—é«”åœ¨ç¡çœ -è¦ºé†’èª¿æ§ä¸­çš„è§’è‰²ï¼ŒPitolisant ç‚ºæ²»ç™‚çŒç¡ç—‡çš„æ–°é¸é …</td>
</tr>
<tr>
<td>36169322</td>
<td>Real-life WAKE study in narcolepsy with pitolisant</td>
<td>2022</td>
<td>è§€å¯Ÿæ€§ç ”ç©¶é¡¯ç¤º Pitolisant å°æ—¢å¾€æ²»ç™‚ç„¡æ•ˆçš„çŒç¡ç—‡æ‚£è€…æœ‰æ•ˆï¼ŒæåŠå¤±çœ è©•ä¼°</td>
</tr>
<tr>
<td>30214155</td>
<td>Profile of pitolisant in narcolepsy management</td>
<td>2018</td>
<td>ç³»çµ±æ€§å›é¡§ Pitolisant çš„è—¥æ•ˆå­¸èˆ‡è—¥å‹•å­¸ç‰¹æ€§</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. attention deficit-hyperactivity disorder</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.36%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ7 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32882898/" target="_blank">32882898</a></td><td>2020</td><td>Article</td><td>Medicines (Basel, Sw</td><td>Pitolisant and Other Histamine-3 Receptor Antagonists-An Upd...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34534876/" target="_blank">34534876</a></td><td>2021</td><td>Article</td><td>Epilepsy &amp; behavior </td><td>Drugs for patients with epilepsy and excessive daytime sleep...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24122734/" target="_blank">24122734</a></td><td>2013</td><td>Article</td><td>Drugs</td><td>Current and emerging options for the drug treatment of narco...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27363923/" target="_blank">27363923</a></td><td>2016</td><td>Article</td><td>Behavioural brain re</td><td>Histamine H3 receptor as a potential target for cognitive sy...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30359639/" target="_blank">30359639</a></td><td>2019</td><td>Article</td><td>Neuropharmacology</td><td>Drug-receptor kinetics and sigma-1 receptor affinity differe...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 2 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. faciodigitogenital syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.29%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

### ä¸Šå¸‚ç‹€æ…‹
å°ç£å·²æ ¸å‡†ä¸Šå¸‚ï¼Œå…±æœ‰ 4 å¼µè¨±å¯è­‰ï¼ˆ2 ç¨®åŠ‘é‡è¦æ ¼å„ 2 å¼µï¼‰ã€‚

### ä»£è¡¨æ€§ç”¢å“

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|------|--------------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028103è™Ÿ | å”¯é†’è†œè¡£éŒ 4.5æ¯«å…‹ (Wakix) | è†œè¡£éŒ  | ä¿¡æ±ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | 2026/07/13 |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028104è™Ÿ | å”¯é†’è†œè¡£éŒ 18æ¯«å…‹ (Wakix) | è†œè¡£éŒ  | ä¿¡æ±ç”ŸæŠ€è‚¡ä»½æœ‰é™å…¬å¸ | 2026/07/13 |

### æ ¸å‡†é©æ‡‰ç—‡
1. æ²»ç™‚ 6 æ­²ä»¥ä¸ŠçŒç¡ç—‡ï¼ˆä¼´éš¨æˆ–æœªä¼´éš¨çŒå€’ç¾è±¡ï¼‰
2. æ”¹å–„é˜»å¡æ€§ç¡çœ å‘¼å¸ä¸­æ­¢ (OSA) æˆäººç—…äººçš„è¦ºé†’ç‹€æ…‹ä¸¦æ¸›å°‘æ—¥é–“éåº¦å—œç¡ (EDS)

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

DDInter è³‡æ–™åº«é¡¯ç¤º Pitolisant èˆ‡å¤šç¨®è—¥ç‰©æœ‰äº¤äº’ä½œç”¨ï¼š

**åš´é‡äº¤äº’ä½œç”¨ (Major)**ï¼š
- Bupropionï¼šé™ä½ Pitolisant ä»£è¬ï¼Œå¢åŠ è¡€ä¸­æ¿ƒåº¦
- Dolasetronï¼šå¯èƒ½å»¶é•· QT é–“è·

**ä¸­åº¦äº¤äº’ä½œç”¨ (Moderate)**ï¼š
- H2 å—é«”é˜»æ–·åŠ‘ï¼šFamotidine, Cimetidine
- çš®è³ªé¡å›ºé†‡ï¼šHydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide
- å…¶ä»–ï¼šMetformin, Morphine, Clarithromycin, Levofloxacin
- ç€‰åŠ‘ï¼šBisacodyl, Polyethylene glycol

### æ³¨æ„äº‹é …
1. **QT å»¶é•·é¢¨éšª**ï¼šé¿å…èˆ‡å…¶ä»–å»¶é•· QT è—¥ç‰©ä½µç”¨
2. **CYP3A4 èª˜å°**ï¼šå¯èƒ½é™ä½ä½µç”¨è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ï¼ˆå¦‚å£æœé¿å­•è—¥ï¼‰
3. **è‚è…åŠŸèƒ½ä¸å…¨**ï¼šä¸­é‡åº¦è‚åŠŸèƒ½ä¸å…¨éœ€æ¸›é‡
4. **æ‡·å­•/å“ºä¹³**ï¼šä¸å»ºè­°ä½¿ç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**èºé¬±ç—‡** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Psychotic Disorders** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Arrhythmias, Cardiac** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå¿ƒå¾‹ä¸æ•´ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Hepatic Insufficiency** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬åƒ¹å€¼è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | æ–‡ç»æ”¯æŒ | è‡¨åºŠè©¦é©— | ç¸½è©• |
|------------|----------|----------|----------|------|
| å¤±çœ  | L3 | 8 ç¯‡ | 1 (é–“æ¥) | ä¸­åº¦æ”¯æŒ |
| ADHD | L3-L4 | 7 ç¯‡ | 0 | è¼•åº¦æ”¯æŒ |
| Aarskog ç—‡å€™ç¾¤ | L5 | 0 | 0 | ç„¡æ”¯æŒ |

### å»ºè­°
1. **ADHD**ï¼šåŸºæ–¼ H3 å—é«”åœ¨èªçŸ¥åŠŸèƒ½çš„è§’è‰²ï¼Œå€¼å¾—é€²ä¸€æ­¥æ¢ç´¢ï¼Œä½†ç›®å‰ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—
2. **å¤±çœ **ï¼šçœ‹ä¼¼çŸ›ç›¾ä½†æ”¹å–„ç¡çœ -è¦ºé†’é€±æœŸèª¿æ§å¯èƒ½å°æŸäº›ç¡çœ éšœç¤™æœ‰ç›Šï¼Œéœ€æ›´å¤šç ”ç©¶
3. Pitolisant ç›¸å°æ–°ç©ï¼ˆå°ç£ 2021 å¹´æ ¸å‡†ï¼‰ï¼Œè‡¨åºŠç¶“é©—ä»åœ¨ç´¯ç©ä¸­

---
*æœ¬ç­†è¨˜ç”± TwTxGNN ç³»çµ±è‡ªå‹•ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*ç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Titanium Dioxide]({{ "/drugs/titanium_dioxide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Metoprolol]({{ "/drugs/metoprolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Atezolizumab]({{ "/drugs/atezolizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Etanercept]({{ "/drugs/etanercept/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Pitolisantè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/pitolisant/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_pitolisant,
  title = {Pitolisantè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pitolisant/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
